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Highlights: 
 Current imaging studies are limited by methodological heterogeneity, potential 
accrual bias and lack of an independent reference standard for lesions 
 Meta-analysis is not possible currently due to the quality of studies to date. 
 Further prospective research is required to assess the impact on 
management 
 
Abstract 
Objectives: To undertake a systematic review to determine the diagnostic 
performance of whole body MRI (WBMRI) including diffusion weighted sequences 
(DWI) compared to whole body computed tomography (WBCT) or 18F-
fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) in patients 
with myeloma.  
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Methods: Two researchers searched the primary literature independently for 
WBMRI studies of myeloma. Data were extracted focusing on the diagnostic ability 
of WBMRI versus WBCT and 18F-FDG PET/CT. Meta-analysis was intended.  
Results: 6 of 2857 articles were eligible that included 147 patients, published from 
2008-2016. Studies were heterogeneous including both newly diagnosed & relapsed 
patients. All were single centre studies. Four of the six studies (66.7%) accrued 
prospectively and 5/6 (83.3%, 3 prospective) included WBMRI and 18F-FDG 
PET/CT. Three of seven (42.9%) included DWI. The lack of an independent 
reference standard for individual lesions was noted in 5/6 (83.3%) studies. Studies 
reported that WBMRI detected more lesions than 18F-FDG PET/CT (sensitivity 68-
100% versus 47-100%) but was less specific (specificity 37-83% versus 62-85.7%). 
No paper assessed impact on management. 
Conclusions: Studies were heterogeneous, the majority lacking an independent 
reference standard. Future prospective trials should address these limitations and 
assess the impact of WBMRI on management. 
 
Key words: 
Multiple myeloma, whole-body MRI, 18F-FDG PET/CT, whole-body CT, DWI 
 
1. INTRODUCTION 
Myeloma is a haematological malignancy characterised by the clonal proliferation of 
plasma cells and excessive monoclonal protein in the blood and/or urine. For many 
patients, it is a debilitating disease causing unremitting bone pain and pathological 
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fractures with a 5 year survival rate of 47% [1]. Diagnosis of active multiple myeloma 
as defined by the IMWG classically relies on histological confirmation of plasma cell 
infiltration of the bone marrow with clonal bone marrow plasma cells ≥10% (or 
extramedullary plasmacytoma) and any one of the following CRAB (calcium, renal, 
anaemia, bone) features: hypercalcaemia, renal insufficiency, anaemia and bone 
lesions.  Almost all cases of myeloma are preceded by a premalignant asymptomatic 
stage, monoclonal gammopathy of undetermined significance (MGUS) [2; 3]. The 
trigger for progression from MGUS to myeloma is poorly understood but multi-
factorial including genetic mutations and alterations in the bone marrow 
microenvironment favouring clonal proliferation [4; 5].  
The role of imaging in myeloma has evolved in recent years due to the increasing 
availability of high platform imaging: computed tomography (CT), magnetic 
resonance imaging (MRI) and integrated positron emission tomography/CT 
(PET/CT)[6-19]. There is currently a lack of reference standard for lesions. Although 
skeletal survey is accepted by the EMN imaging algorithm, CT has now been 
integrated into the diagnostic criteria and has been shown to be more sensitive in the 
detection of lesions and easy to perform [20; 21]. Since myeloma can affect any 
marrow-containing bone, an assessment of the whole skeleton by cross-sectional 
imaging is required in patients with either 10 – 60% plasma cells on their biopsy or 
an M-protein of ≥30g/L. It is recognised that the axial skeleton is the main site of 
disease in the majority of patients [22] with only 10% of patients present with extra-
axial disease only. Extra-medullary involvement in myeloma is rare, estimated to be 
around 3.4% at diagnosis [23] and is associated with a poor prognosis. 
The new International Myeloma Working Group (IMWG) definition of myeloma 
includes the presence more than one unequivocal focal lesion (≥5mm) by cross-
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sectional imaging as a diagnostic criterion for myeloma [24]. Nevertheless, it remains 
unclear which cross-sectional imaging modality is advantageous at initial 
assessment and what their impact on subsequent management is. To this end we 
performed a systematic review of the available medical literature, focussing on the 
diagnostic performance of whole body MRI (WBMRI) including diffusion weighted 
imaging (DWI) compared to whole body computed tomography (WBCT) and 18F-
fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) in the 
initial assessment of myeloma, to identify if there is sufficient evidence for WBMRI to 
replace WBCT or 18F-FDG PET/CT, and the impact of WBMRI on subsequent 
management. 
2. METHODS 
2.1. Data sources and search strategy 
Inclusion criteria 
We identified primary studies comparing WBMRI ± DWI with 18F-FDG PET/CT or 
WBCT in the diagnosis of patients with myeloma. PUBMED and EMBASE 
databases were included in the literature search. We combined terms in the 
following search string to identify relevant studies: 
“Myeloma, multiple myeloma, smouldering myeloma, whole body MRI, whole body 
magnetic resonance imaging, magnetic resonance imaging, MRI, diffusion 
weighted MRI, DWI, DW-MRI, 18F-FDG PET/CT, 18F-FDG positron emission 
tomography, PET, whole body CT, whole body computed tomography, CT”. 
Exclusion criteria 
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Results were then limited to humans (using: AND "humans"[MeSH Terms]), limited 
to English and French language (using: AND English[lang], AND French[lang]). We 
used the systematic review filter (AND pmh_sr[sb]) to identify prior systematic 
reviews and reviewed the initial search (i.e. excluding filters) to identify any articles 
excluded incorrectly.  
Electronic abstracts of identified studies were read and the following exclusion 
criteria applied. Case reports, small cases series (less than 10 patients), narrative 
reviews, letters/correspondence and conference abstracts were excluded since 
these would not contribute sufficient unbiased data able to answer our research 
question. Studies outwith of the diagnostic setting were also excluded. An excluded 
study log recorded reasons for exclusions. 
The search was performed by 2 radiologists with a specialist interest in oncological 
imaging (>7 & 15 years’ imaging experience, respectively) and any disagreement 
was resolved by consensus. 
2.2. Data Extraction 
Data were extracted from full articles by each radiologist independently into a 
database (Excel, Microsoft, Redmond WA). For each article, the first author, 
publication year, primary characteristics of the study (sample size, age, gender, 
single or multicentre study, and whether accrual was prospective or retrospective), 
imaging parameters (type of imaging, scanning sequence, MRI field strength, DWI b 
value, tracer administered activity, analysis technique) reference standard and 
diagnosis method were recorded. We designated WBMRI including diffusion 
weighted sequences as the index test. We designated WBCT as the imaging 
reference standard for the analysis of focal lesions. 
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2.3. Quality Assessment 
To assess the quality of the eligible studies in terms of generalisability and risk of 
bias, the quality assessment for studies of diagnostic accuracy tool (QUADAS-2) 
[25] was utilised covering the following domains: patient selection, index test, 
reference standard, and flow of patients through each study. Questions within each 
of the domains was scored as ‘yes’, ‘no’ or ‘unclear’. Factors such as study design 
(retrospective or prospective), reference standard or imaging characteristics (1.5T or 
3T-MRI, DWI b-value, skeletal coverage) were assessed for potential 
bias/heterogeneity. 
 
2.4. Meta-analysis 
We intended at outset to perform a meta-analysis to obtain pooled estimate of 
sensitivity and specificity. However meta-analysis was prevented by the small 
number of studies retrieved that presented adequate data, combined with excessive 
methodological heterogeneity.  
 
3. RESULTS 
We followed PRISMA guidelines for transparent reporting of systematic reviews. 
3.1. Eligible studies 
The initial search performed on 6 January 2017 yielded 2879 articles, after removing 
duplicates 2847 remained. 2816 articles were excluded following evaluation of 
abstracts. The remaining 31 articles were retrieved in full text, and eventually 6/31 
(19.4%) studies were included in the systematic review [26-32], of which 5/6 
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(83.3%) compared WBMRI with 18F-FDG PET/CT and 1/6 (16.7%) with WBCT; 3/6 
(50.0%) included DWI. The PRISMA flow chart is shown in Figure 1. Four of the 6 
(66.7%) studies were performed prospectively. Two of the 6 (33.3%) studies 
reported imaging results at diagnosis, the remainder included imaging at both 
diagnosis and during follow-up. Five of the 6 (83.3%) studies compared WBMRI to 
18F-FDG PET/CT. The remaining study compared WBMRI with WBCT.  
Figure 1. Flow of studies through the selection process. 
 
 
 
 
 
 
 
 
 
 
 
3.2. Patient population 
Records identified through database searching (n 
=2879) 
Pubmed (n=1909), Embase (n =970), duplicates 
(n=64) 
Records after duplicates removed 
(n = 2847 ) 
Studies excluded based 
on title and abstract 
(n = 2816 ) 
Full-text articles 
assessed for eligibility  
(n = 31 ) 
Studies included in 
systematic review 
(n =  6 ) 
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Characteristics for included studies are described in Table 1.1. 147 patients were 
included in the studies with an individual range between 19 and 41. All of the 
studies enrolled patients with a diagnosis of myeloma but included both new and 
previously treated relapsed patients; 1 study also included patients with MGUS. 
Patient age range was 39 to 88 years. Of studies stating gender, 61 (48%) patients 
were male. None were multicentre studies. Spectrum bias influencing patient accrual 
was potentially present in 2/6 studies (33.3%) as accrual was retrospective and 
relied upon identifying patients via a database and keyword search. All identified 
studies were European in origin (Germany, Italy, France, UK, Republic of Ireland). 
Table 1. Study Characteristics 
Author 
Year 
Sample 
size 
Patient 
type 
Timing 
of 
imaging 
Singl
e or 
Multi- 
Centr
e 
Accrual Index 
Test 
Reference 
Test 
Lesions 
MR 
Field 
Strengt
h 
(Tesla) 
MRI 
Sequence 
DWI 
b-
value 
s/mm2 
FDG 
Tracer 
administere
d activity 
MBq 
Baur-
Melnyk 
2008 
n=41 
Myelo
ma 
Diagnosis Single Prospective MRI CT 1.5 STIR 
T1 
N/A N/A 
Shortt 
2009 
n=24 
Myelo
ma 
 
Diagnosis 
Follow-up 
Single Prospective MRI, 
18F-
FDG 
PET/C
T 
None 1.5 STIR  
T1  
 
N/A 250-440  
Cascini 
2013 
n=22 
Myelo
ma 
Diagnosis 
Follow-up 
Single Prospective  MRI 
18F-
FDG 
PET/C
T 
None 1.5 STIR 
T1  
N/A 370 
Sachpekid
is 
2015 
n=24 
 
Myelo
ma 
 
Diagnosis 
Follow-up 
Single Prospective DWI, 
18F-
FDG 
PET/C
T 
 CT of 
PET/CT 
3 STIR 
T1 
T2 
DWI 
0, 800  
Brillet 
2012 
Myelo
ma 
Diagnosis Single Retrospectiv
e 
MRI 
18F-
None 1.5 STIR 
T1 
0, 800 5* 
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 MRI Sequence: STIR: Short tau inversion recovery, DWI: Diffusion weighted imaging; *5MBq/kg 
 
3.3. Quality assessment 
Methodological quality as assessed using the QUADAS criteria are presented in 
Figure 2. Selection criteria was clearly described in 5/6 studies (83.3%). With 
respect to the index test in 5/6 studies, 2 index tests were used. While all studies 
included biopsy-proven myeloma patients, in 4/6 studies an independent imaging 
reference test was not used for lesions identified and this constituted a major 
limitation. In 1 study CT was used as an independent reference standard, however, 
the time period between the index and reference test was only stated in 1 study 
and CT only performed independently in 1 study. A blinding method was not used 
during interpretation of the index test and reference standard; thus there was a clear 
risk of bias.  
 
n=19 MGUS FDG 
PET/C
T 
DWI 
Pawlyn 
2016 
n=17 
Myelo
ma 
Diagnosis 
Follow-up 
Single Retrospectiv
e 
MRI 
18F-
FDG 
PET/C
T 
None 1.5 DWI  50, 
900 
400 
  Risk of bias       Applicability concerns   
  
Patient 
selection Index test 
Reference 
standard 
Flow and 
timing Patient selection 
Index 
test 
Reference 
standard 
Baur-Melnyk et 
al. + + + + + - - 
Brillet et al. + - - - + - + 
Cascini et al. + ? ? - + - + 
Pawlyn et al. ? ? ? ? ? - + 
Sachpekidis et 
al. + - - + + - - 
Shortt al.  + ? - + + - + 
AC
CE
PT
ED
 M
AN
US
CR
IPT
+ = yes, - = no, ? = unclear 
Figure 2. QUADAS-2 Quality assessment 
 
 
 
 
There was heterogeneity in imaging acquisition (Table 2). The majority of MRI was 
performed at 1.5T (5/6, 83.3%) with skeletal coverage from skull vertex to ankles in 
3/6, 50.0%) and to mid-thigh in the remainder. Individual MRI sequences varied in 
each study: short tau inversion recovery (STIR) and T1 spin echo (SE) or turbo spin 
echo (TSE) were performed most commonly. DWI b-values were either 0,800 s/mm2 
or 50, 900 s/mm2 in 50% respectively.  
 
Table 2. WBMRI, 18F-FDG PET/CT & CT Acquisition Characteristics 
 
Author 
Year 
Sample size 
MR 
Field 
Strength 
(Tesla) 
MRI 
Sequence 
Standard 
MRI 
Orientation 
Slice 
thickness 
Coverage DWI 
Orientation 
Slice 
thickness 
DWI 
b-
value 
s/mm2 
FDG 
Tracer 
Dose 
MBq 
CT 
component 
Orientation 
Slice 
thickness 
Baur-Melnyk 
2008 
n=41 
Siemens 
1.5 
STIR 
T1 SE 
Axial 
STIR/T1:  
Skull 
Coronal 
STIR/T1: 
Thorax, 
Pelvis, Legs 
Skull 
Vertex to  
ankles 
N/A N/A N/A Axial  
3mm* 
  Risk of bias       Applicability concerns   
  Patient selection Index test 
Reference 
standard Flow and timing Patient selection 
Index 
test 
Reference 
standard 
Baur-Melnyk et al. + + + + + - - 
Brillet et al. + - - - + - + 
Cascini et al. + ? ? - + - + 
Pawlyn et al. ? ? ? ? ? - + 
Sachpekidis et al. + - - + + - - 
Shortt al.  + ? - + + - + 
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Sagittal 
STIR/T1:  
Spine 
5mm 
Shortt 
2009 
n=24 
Phillips 
1.5 
STIR  
T1 TSE 
 
Axial STIR: 
Whole body 
Coronal 
STIR: 
Whole body 
Sagittal T1: 
Whole body 
8mm 
Skull 
Vertex to  
ankles 
N/A N/A 250-440  Axial 
Not specified 
Cascini 
2013 
n=22 
Phillips 
1.5 
STIR 
T1 TSE 
Coronal 
STIR: 
Whole body 
Sagittal T1:  
Spine 
Not specified 
Skull 
Vertex to  
ankles 
N/A N/A 370 Axial 
Not specified 
Sachpekidis 
2015 
n=24 
 
3 STIR 
T1 TSE 
T2 TSE 
DWI 
Coronal 
STIR: 
Whole body 
Coronal T1: 
Whole body 
Sagittal T1: 
Whole body 
Sagittal T2: 
Whole body 
5mm (cor) 
3mm (sag) 
Skull 
Vertex to  
mid-thigh 
Axial DWI: 
Whole body 
 
0,800 Not 
specified 
Axial 
Not specified 
Brillet 
2012 
n=19 
1.5 STIR 
T1 TSE 
DWI 
Coronal 
STIR: 
Whole body 
Sagittal T1: 
Spine 
 
Skull 
vertex to 
mid-thigh 
Axial DWI: 
Whole body 
 
800 5+ Axial 
3.75mm 
Pawlyn 
2016 
n=17 
1.5 DWI  N/A Skull 
vertex to 
knees 
Axial DWI: 
Whole body 
 
50,900 400 Axial  
Not specified 
SE: spin echo; TSE: turbo spin echo, STIR: short tau inversion recovery, DWI: diffusion weighted imaging 
*CT performed separately; + MBq/kg body weight 
 
3.4. Diagnostic accuracy 
WBMRI versus 18F-FDG PET/CT 
5 studies compared WBMRI to 18F-FDG PET/CT; of these 3/5 (60%) studies used 
DWI in their MRI protocol. PET/CT tracer administered activity varied from 250-440 
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MBq FDG. Only 1/5 (20%) included the CT component of the PET/CT as a reference 
standard for assessing lesions. The remaining studies did not state a reference 
standard for lesions. 18F-FDG PET/CT lesions were defined as a focal increase in 
uptake or a diffuse pattern. Individual studies reported MRI to be more sensitive in 
lesion detection than PET/CT (Table 3) (sensitivity 68-100% versus 47-100%) but 
less specific (specificity 37-83% versus 62-85.7%).  
 
Table 3. Diagnostic accuracy 
Author 
Year 
Sample 
size 
 
Sites 
assessed 
 
Assessment 
method 
 
Comparison 
test 
 
WBMRI 
Sensitivity 
Specificity  
 
18F-FDG PET/CT - 
WBCT 
Sensitivity 
Specificity 
 
Study 
Limitations 
Baur-Melnyk 
2008 
n=41 
Skull vertex 
to ankles 
Consensus reading 
by 2 radiologists. 
Skeleton divided 
into 61 regions, 
each region 
evaluated for 
myeloma 
involvement. 
 
CT 
 
N/A 
 
N/A 
 
Shortt 
2009 
n=24 
Skull vertex 
to ankles 
Independent 
reading by 2 
radiologists, 
marrow 
involvement was 
compared to bone 
marrow aspiration 
and biopsy results. 
 
PET-CT 
 
68% 
83% 
 
59% 
75% 
Lack of 
imaging 
reference 
test 
Cascini 
2013 
n=22 
Skull vertex 
to ankles 
Pattern of bone 
marrow 
involvement 
recorded at 
baseline and 
compared to bone 
marrow aspiration 
and biopsy. 
Second reading 
assessed treatment 
response. 
 
PET-CT 
100% / 
100% 
100% / 
60%* 
100% / 82% 
78% / 80 % * 
Lack of 
imaging 
reference 
test 
Sachpekidis 
2015 
n=24 
 
Skull vertex 
to mid- thigh 
Visual analysis for 
suspicious foci of 
myeloma 
performed by 2 
nuclear medicine 
physicians and 2 
radiologists. 
 
CT  
 
77% * 
90% ** 
 
47%* 
90% ** 
 
Brillet 
2012 
n=19 
Skull vertex 
to mid- thigh 
Visual analysis for 
suspicious lesions 
performed by a 
nuclear medicine 
physician and a 
radiologist 
independently. 
 
PET-CT 
 
100% 
37% 
 
100% 
62% 
Lack of 
imaging 
reference 
test 
Pawlyn 
2016 
Skull vertex 
to knees 
Consensus reading 
by 2 radiologists for 
defined body 
 
PET-CT 
 
N/A 
 
N/A 
Lack of 
imaging 
reference 
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n=17 regions to assess 
disease burden. 
Compared to bone 
marrow results. 
test 
*after treatment 
** mixed population (before and after treatment) 
 
WBMRI versus WBCT 
Only 1 study has compared WBMRI to WBCT. The detection rate of bone lesions 
on WBMRI to WBCT in these 41 patients at diagnosis were statistically higher with 
understaging in 11 patients with WBCT (Table 3). 
 
3.5. Impact on management 
No study assessed impact on initial management thus current data are insufficient to 
draw any conclusions on the impact on management.  
 
4. DISCUSSION 
The limitations of skeletal survey and WBCT for the assessment of myeloma are well 
known and have been documented previously [33]. In particular, these techniques 
detect bone destruction and thus have a limited ability for marrow infiltration [26-32]. 
This has led to other imaging methods that can detect marrow involvement to be 
considered within the patient pathway including WBMRI and 18F-FDG PET/CT, with 
the aim of ruling in disease (i.e. a sensitive test with a minimal proportion of false 
negatives).  
 
Advances in imaging technology have reduced the acquisition time of WBMRI and 
allowed for sequences such as DWI to be incorporated within an acceptable on-table 
time. The introduction of multichannel coils, higher gradient amplitudes, introduction 
AC
CE
PT
ED
 M
AN
US
CR
IPT
of parallel imaging, and improved sequences including echo planar imaging have 
benefited DWI in particular. WBMRI with DWI in patients with myeloma aims to 
maximise detection of diffuse marrow infiltration as well as focal lesions and extra-
osseous disease yet maintaining anatomical detail [34]. Several studies have already 
documented the potential of whole-body DWI, particularly for staging other tumour 
entities [35-39]. 
 
Hillengass et al. investigated the prognostic significance of focal lesions in WBMRI in 
asymptomatic patients and showed that the presence of lesions in a number greater 
than 1 were the strongest adverse prognostic factors for progression to symptomatic 
MM [46]. All of these groups used clinical criteria as reference standards; there was 
no imaging reference standard used. 
 
The diagnostic criteria for myeloma were revised and published in 2014 by the 
International Myeloma Working Group (IMWG). Apart from the CRAB criteria, three 
biomarkers of malignancy have been included as myeloma defining events. The 
presence of at least one of these biomarkers will be sufficient to diagnose myeloma 
regardless of the CRAB criteria. These biomarkers are more than one lesion 
measuring ≥5mm on MRI studies, clonal bone marrow cell plasma percentage ≥ 60%, 
serum involved/uninvolved free light chain ration of 100 or greater [24]. The IMWG 
also recommends the use of low-dose WBCT, 18F-FDG PET/CT or WBMRI in the 
initial work-up of patients with smouldering MM [47].  
 
This systematic review confirms the lack of robust imaging evidence to support 
clinical practice. The impact of imaging on management has not been analysed by 
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any of the studies identified and included in this systematic review. The published 
data suggest that WBMRI is more sensitive but less specific than 18F-FDG PET/CT. 
The papers included did not provide lesion verification by either biopsy or follow-up 
of individual lesions. However, we found that the existing single centre studies were 
extremely heterogeneous with a mixed population of patients (newly diagnosis/pre-
treated myeloma), anatomical variation in imaging coverage of the skeleton, 
variations in acquisition protocols used and a problematic lack of independent 
reference standard for individual lesions.  
 
The inclusion of both newly diagnosed and post therapy patients will also contribute 
to the lower specificity of WB-MRI as anatomical changes after treatment take longer 
to normalise (up to 12 months) and may mask new sites of disease. The use of 
limited anatomical MRI sequences, most commonly STIR and T1 SE or TSE also 
contribute to the lack of specificity, limiting lesion characterisation. Further study of 
newer sequences including T1 DIXON (allowing the generation of separate fat and 
proton weighted images in addition to the standard T1-weighted in and opposed 
phase images, and thus providing different contrast) are warranted for this.  
 
The use of intravenous contrast administration should also be considered in future 
given the neovascularisation associated with diffuse bone marrow involvement in 
myeloma [48], although it is recognised that in a proportion of patients this will not be 
possible due to underlying renal impairment. Initial studies have explored the use of 
contrast enhancement and dynamic contrast enhancement [40; 41; 48-52] and 
shown that there is an increased microvessel density resulting in higher contrast 
enhancement in some myeloma patients with a good agreement in staging when 
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comparing contrast enhanced T1-sequences with both DWI and clinical data. Whole-
body MRI with contrast enhancement has also been used as a tool in treatment 
assessment. 
 
Another major consideration is the use of multiple index tests and lack of a good 
reference standard in all studies which included WBMRI and 18F-FDG PET/CT. The 
lack of blinding between index tests and between index test and a non-independent 
reference standard will introduce further bias. No studies performed histological 
confirmation of focal lesions. This has to be addressed in future studies.  
 
The lack of multicentre data is also of concern. Single centre studies are typically 
from centres with strong expertise. At present WBMRI remains untested in the 
multicentre setting and its generalisability is unknown. The technical challenges of 
multiple scanners, multiple vendors, different magnet strengths, and sequences are 
known to influence MRI quality and can impact on diagnostic accuracy. As yet there 
are no published data in this arena.  
 
The role and technical aspects of DWI also need to be further evaluated. Of the 
studies included only 4/6 performed DWI using either b-values of 0,800 and 50, 900 
s/mm2 in each of 2 studies, respectively. Only 2 b-values are typically used in WB 
DWI studies due to the acquisition time related to using >2 b-values. Lower b-value 
images have a higher signal-to-noise ratio (SNR) but are influenced by perfusion 
effects; higher b-values highlight the differences in diffusion of a tissue or lesion but 
have an inferior SNR [53].  
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There are currently no guidelines concerning the most appropriate b-value in this 
clinical setting. The National Cancer Institute consensus statement has 
recommended a high b-value between 750 and 1000s/mm2 for qualitative tumour 
evaluation in whole-body imaging [36] and the use of three b-values to enable the 
calculation of perfusion-insensitive ADC values, this should include a b-value of 0 
s/mm2, a b-value of ≥100 s/mm2 and a higher b-value of ≥500 s/mm2. Another 
consensus statement as recommended by the Prostate Cancer Clinical Trials 
Working Group (PCWG) for DWI in metastatic prostate cancer has suggested that 2 
b-values (b50-100 s/mm2 and b800-1000 s/mm2) be used in a core protocol and 3 b-
values for a more comprehensive assessment (additional b500-600 s/mm2). The 
core protocol is aimed at detecting the onset of metastatic disease and the more 
comprehensive assessment for those patients with known metastatic disease and 
those in whom serial tumour response assessments (including clinical trials) are 
planned [54]. To date there is little evidence to support ADC in the diagnostic setting 
though the calculation of mean ADC values has been shown to correlate significantly 
with treatment response and may be implemented as a tool in patient monitoring 
[55].  
 
In conclusion, our systematic review aimed to determine the diagnostic accuracy of 
WBMRI in the initial assessment of myeloma patients and its impact on management 
in comparison with 18F-FDG PET/CT or WBCT. Studies were heterogeneous, with 
biased accrual, and lack of an independent reference standard precluding meta-
analysis. In the future, multicentre studies of WBMRI should be designed to address 
these gaps, in particular paying attention to minimising accrual bias, assessing the 
generalisability of these advanced techniques in the multicentre setting, the impact of 
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different MRI sequences, the impact of standardization of MRI protocols, as well as 
the impact on management and cost-effectiveness of the different cross-sectional 
approaches.  
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